The InPen is pretty cool. I wonder how badly Medtronic will screw it up!
You see this all the time, whenever a small startup gets purchased by a giant conglomerate.
Medtronic, meet Companion Medical. 
Companion Medical… meet bureaucracy and red tape.
I imagine there first screw up will to provide integration to only their CGM.
…and they might only allow injections if your BG is over 150. 
Here is where I would guess big blues lawyers would get involved:
“how insulin dosing data can be shared with platforms like Apple Health, Dexcom’s open-source APIs, Glooko, and others.”
That doesn’t seem very safe. You can imagine the risk averse lawyers saying “We should shut down all sharing immediately…Too much risk”
I wonder if they will make the InPen only compatible with a proprietary Medtronic needle!
Or I wonder if it will be a rewind of a movie we have seen before.
Animas Corporation:
- Founded in 1996
- Acquired by Johnson & Johnson in 2006
- Shutdown in 2017
(They sold their customer database to Medtronic)
you’re probably right.